RECURSION PHARMACEUTICALS, INC. Operating Lease Right-of-Use Assets
RECURSION PHARMACEUTICALS, INC. (RXRX) had Operating Lease Right-of-Use Assets of $40.27 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $40.27M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $42.82M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $45.34M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $47.81M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $40.27M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $42.82M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $45.34M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $47.81M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $50.32M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $53.19M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $65.88M 10-K · filed 2026-02-25 |
| 2024-09-30 | $47.88M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $44.09M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $35.50M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $33.66M 10-K · filed 2025-02-28 |
| 2023-09-30 | $34.06M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $34.90M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $35.12M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $33.26M 10-K · filed 2024-02-29 |
| 2022-09-30 | $33.73M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $34.64M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $33.30M 10-Q · filed 2022-05-10 |
| 2022-01-01 | $32.90M 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |